RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Outlook Therapeutics Stock

Outlook Therapeutics ROCE 2024

Outlook Therapeutics ROCE

3.68

Ticker

OTLK

ISIN

US69012T2069

WKN

A2PF3C

In 2024, Outlook Therapeutics's return on capital employed (ROCE) was 3.68, a -150.98% increase from the -7.22 ROCE in the previous year.

Outlook Therapeutics Aktienanalyse

What does Outlook Therapeutics do?

Outlook Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for eye diseases. The company was originally established in 2010 under the name Oncobiologics. Initially, the company focused on the development of biosimilar products to improve access and reduce costs of biologics. The goal was to bring cheaper alternatives to the market that were equivalent to approved original products. In 2018, the company decided to shift its focus to the development of ophthalmological therapeutics. Oncobiologics was rebranded as Outlook Therapeutics Inc, and the development of biosimilar products was discontinued. Instead, the company has since been focused on researching and developing eye therapies to provide better treatment options for patients with serious eye diseases. The business model of Outlook Therapeutics Inc is primarily based on the development and marketing of high-quality, patented medications for eye diseases. The company utilizes innovative technologies and research approaches to maximize the effectiveness and safety of its products. It works closely with leading experts and clinicians in the field of ophthalmology to ensure that the therapies meet the needs of patients. One of the key areas of Outlook Therapeutics Inc is the development of therapeutics for wet age-related macular degeneration (AMD). Wet AMD is a progressive degenerative eye disease that can lead to rapid vision deterioration. Currently, there are already various medications on the market for treating this condition. However, Outlook Therapeutics Inc is working on developing new therapeutics that have improved effectiveness, longer duration of action, and fewer side effects than existing medications. Another important area for the company is the development of therapeutics for diabetic macular edema, a disease that can occur in individuals with type 2 diabetes. The company is researching improved treatments for this condition, which can often lead to blindness. Outlook Therapeutics Inc offers a variety of products aimed at improving patients' visual capabilities. In addition to the aforementioned medications, the company also provides medication combinations and drugs with special active ingredients. Through continuous research and development, Outlook Therapeutics Inc constantly expands and optimizes its offerings to meet the needs of patients in the field of eye therapy. Overall, the business model of Outlook Therapeutics Inc is focused on advancing the research and development of new therapies for eye diseases. Through innovative technologies and collaboration with experts in the field of ophthalmology, the company aims to improve the quality of life for patients with severe eye diseases and provide them with better treatment options. Outlook Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Outlook Therapeutics's Return on Capital Employed (ROCE)

Outlook Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Outlook Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Outlook Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Outlook Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Outlook Therapeutics stock

What is the ROCE (Return on Capital Employed) of Outlook Therapeutics this year?

The ROCE of Outlook Therapeutics is 3.68 undefined this year.

How has the ROCE (Return on Capital Employed) of Outlook Therapeutics developed compared to the previous year?

The ROCE of Outlook Therapeutics has increased by -150.98% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Outlook Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Outlook Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Outlook Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Outlook Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Outlook Therapeutics impact the company?

An increase in the ROCE of Outlook Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Outlook Therapeutics affect the company?

A decrease in ROCE of Outlook Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Outlook Therapeutics?

Some factors that can affect Outlook Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Outlook Therapeutics so important for investors?

The ROCE of Outlook Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Outlook Therapeutics take to improve the ROCE?

To improve the ROCE, Outlook Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Outlook Therapeutics pay?

Over the past 12 months, Outlook Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Outlook Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Outlook Therapeutics?

The current dividend yield of Outlook Therapeutics is .

When does Outlook Therapeutics pay dividends?

Outlook Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Outlook Therapeutics?

Outlook Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Outlook Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Outlook Therapeutics located?

Outlook Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Outlook Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Outlook Therapeutics from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Outlook Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Outlook Therapeutics in the year 2023?

In the year 2023, Outlook Therapeutics distributed 0 USD as dividends.

In which currency does Outlook Therapeutics pay out the dividend?

The dividends of Outlook Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Outlook Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Outlook Therapeutics

Our stock analysis for Outlook Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Outlook Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.